Literature DB >> 35904634

Atypical femur fractures associated with bisphosphonate therapy: post-operative outcomes.

Benjamin Murphy1, Sam L Francis1,2, Isaac Rhee1, Sina Babazadeh1,2, James Stoney1, Jarrad Stevens3,4.   

Abstract

PURPOSE: Bisphosphonates are commonly used medication for the treatment of osteoporosis, and a well-established complication of this medication is bisphosphonate-associated atypical femur fractures (BAAFFs). The aim of this study was to assess the post-operative functional and radiographic outcomes of surgically treated BAAFFs.
METHODS: An analysis of patients treated at a university-affiliated institution was performed. Patients who had undergone surgical fixation for a subtrochanteric or shaft of femur fracture which had been classified as atypical and treated with bisphosphonate therapy at the time of fracture were included. The outcome measures assessed included post-operative complications, length of stay, discharge destination, post-operative function, independence in activities of daily living (ADLs) and fracture union.
RESULTS: Twenty patients were included in this study with a mean age of 75.2 years. The cohort was predominantly female. The average duration of bisphosphonate therapy was 7.35 years. Nine patients had contralateral bisphosphonate-related stress reactions at the time of their initial fracture and underwent prophylactic surgical intervention. The majority of patients received cephalomedullary nail fixation (95%) with more than half (65.0%) of the cohort experiencing one or more post-operative complications. The median length of stay was 6.5 days and 50% of the cohort required inpatient rehabilitation. At final review, independent mobilisation was recorded in only 10.0% of patients, and 70% of patients were dependent with their ADLs at their latest follow-up. Average follow-up was 8 months, and only six cases demonstrated union at the six-month review, with delayed union between 9 and 12 months being common.
CONCLUSION: Patients with BAAFFs experience high rates of complications, record poor post-operative functional outcomes, and demonstrate a delayed time to union. Nearly half of our cohort had radiographic evidence of bilateral pathology.
© 2022. The Author(s), under exclusive licence to Springer-Verlag France SAS, part of Springer Nature.

Entities:  

Keywords:  Atypical femoral fracture; Bisphosphonate; Functional outcome; Radiological outcome

Year:  2022        PMID: 35904634     DOI: 10.1007/s00590-022-03314-y

Source DB:  PubMed          Journal:  Eur J Orthop Surg Traumatol        ISSN: 1633-8065


  20 in total

1.  Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

Authors:  Dennis M Black; Michael P Kelly; Harry K Genant; Lisa Palermo; Richard Eastell; Christina Bucci-Rechtweg; Jane Cauley; Ping Chung Leung; Steven Boonen; Arthur Santora; Anne de Papp; Douglas C Bauer
Journal:  N Engl J Med       Date:  2010-03-24       Impact factor: 91.245

Review 2.  Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis.

Authors:  Lydia Gedmintas; Daniel H Solomon; Seoyoung C Kim
Journal:  J Bone Miner Res       Date:  2013-08       Impact factor: 6.741

3.  Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women.

Authors:  Laura Y Park-Wyllie; Muhammad M Mamdani; David N Juurlink; Gillian A Hawker; Nadia Gunraj; Peter C Austin; Daniel B Whelan; Peter J Weiler; Andreas Laupacis
Journal:  JAMA       Date:  2011-02-23       Impact factor: 56.272

4.  Is surgery necessary for femoral insufficiency fractures after long-term bisphosphonate therapy?

Authors:  Yong-Chan Ha; Myung-Rae Cho; Ki Hong Park; Shin-Yoon Kim; Kyung-Hoi Koo
Journal:  Clin Orthop Relat Res       Date:  2010-09-24       Impact factor: 4.176

5.  Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features.

Authors:  Andrea Giusti; Neveen A T Hamdy; Olaf M Dekkers; Sharita R Ramautar; Sander Dijkstra; Socrates E Papapoulos
Journal:  Bone       Date:  2010-12-31       Impact factor: 4.398

6.  Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis.

Authors:  Bo Abrahamsen; Pia Eiken; Richard Eastell
Journal:  J Clin Endocrinol Metab       Date:  2010-09-15       Impact factor: 5.958

7.  Bisphosphonate use and atypical fractures of the femoral shaft.

Authors:  Jörg Schilcher; Karl Michaëlsson; Per Aspenberg
Journal:  N Engl J Med       Date:  2011-05-05       Impact factor: 91.245

8.  Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.

Authors:  Joseph D Isaacs; Louis Shidiak; Ian A Harris; Zoltan L Szomor
Journal:  Clin Orthop Relat Res       Date:  2010-08-31       Impact factor: 4.176

Review 9.  Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review.

Authors:  Carolyn J Crandall; Sydne J Newberry; Allison Diamant; Yee-Wei Lim; Walid F Gellad; Marika J Booth; Aneesa Motala; Paul G Shekelle
Journal:  Ann Intern Med       Date:  2014-11-18       Impact factor: 25.391

10.  Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.

Authors:  Dennis M Black; Erik J Geiger; Richard Eastell; Eric Vittinghoff; Bonnie H Li; Denison S Ryan; Richard M Dell; Annette L Adams
Journal:  N Engl J Med       Date:  2020-08-20       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.